MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Esophageal Cancer
Interventions
DRUG

PD-1 monoclonal antibody consolidation therapy

PD-1 monoclonal antibody-based consolidation therapy for 1 year after completion of radiotherapy (or combination chemotherapy up to 4 cycles if less than 4 cycles of chemotherapy). Specific dosing: PD-1 monoclonal antibody, 200mg every 3 weeks.

Trial Locations (1)

100021

RECRUITING

Cancer hospital, CAMS, Beijing

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Hebei Medical University Fourth Hospital

OTHER

collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER